Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Cartágenes,M.S.S. (2) Garcia,J.B.S. (2) Rodrigues,T.A. (2) Bonfim,B.F. (1) Freire,A.O. (1) Nunes,I.D.P. (1) Sampaio Junior,A.J.B. (1) Mais... Palavra-chave Osteoarthritis (2) Pain (2) Strontium ranelate (2) Treatment (2) Prophylaxis (1) Symptoms (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2018 (1) 2017 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Effect of strontium ranelate on pain behavior in an experimental model of osteoarthritis BJMBR Rodrigues,T.A.; Sampaio Junior,A.J.B.; Nunes,I.D.P.; Cartágenes,M.S.S.; Garcia,J.B.S.. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects of decreasing the risk of fractures and an indication of reducing the progression of osteoarthritis (OA). This study aimed to investigate the effects of SrRan as either a prophylactic or a treatment drug, using an OA rat model to assess pain behavior. A monoiodoacetate (MIA)-induced knee joint OA model in Wistar rats was used. Thirty Wistar rats (both sexes, 60 days old) were distributed in five groups of 6 rats each: the control group, that received no intervention; a prophylactic group, that received oral administration of 25 mg·kg-1·day-1 of SrRan for 28 days before induction of OA; a group treated with 25 mg·kg-1·day-1 of SrRan for 28 days after OA... Tipo: Info:eu-repo/semantics/article Palavras-chave: Osteoarthritis; Strontium ranelate; Pain; Treatment; Prophylaxis. Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000900602 Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review BJMBR Rodrigues,T.A.; Freire,A.O.; Bonfim,B.F.; Cartágenes,M.S.S.; Garcia,J.B.S.. Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory... Tipo: Info:eu-repo/semantics/article Palavras-chave: Osteoarthritis; Strontium ranelate; Treatment; Pain; Symptoms. Ano: 2018 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000800302 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco